CERBOMED
More than 500,000 patients suffer from epilepsy in Italy. Not all of them can be treated sufficiently with available anticonvulsive medication. Therefore the medical device company cerbomed GmbH from Erlangen, Germany, announces that, from March 2013 on, transcutaneous vagus nerve stimulation (t-VNS) with NEMOS will be available to Italian epilepsy patients. To address the Italian market, cerbomed is cooperating with MARVAMED, a medical devices sales specialist experienced in the Italian neurology market. This is the first, successful step in extending into new European markets. Cooperations with further European distributors should follow in the course of the year.
MARVAMED's managing director, Dr. Pierluigi Bertolotto, has more than 20 years’ experience in neuromodulation and neurosurgery. He has both technical know-how and a network with experts in the field of epilepsy. His company, MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery. "Hard-to-treat epilepsy patients suffer severely, and currently there are only a few therapy alternatives. I am glad to announce that with the transcutaneous vagus nerve stimulator NEMOS , a promising therapy option is now available in Italy, too", Bertolotto declares.
"We are happy to cooperate with MARVAMED. Such an effective and experienced sales partner will let us offer t-VNS with NEMOS to patients in Italy", says Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.
About t-VNS with NEMOS
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
With NEMOS cerbomed developed and patented a special stimulator and a dedicated ear electrode for treatment of epilepsies with t-VNS. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
About cerbomed
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
In 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus Nerve Stimulation for the treatment of epilepsies and depression, in 2012 for the treatment of pain.
Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
NEMOS is already available for treating epilepsies in Germany and Austria, and in Italy from March 2013. Forthcoming cooperations with other distributors should make NEMOS available to epilepsy patients in Great Britain, France and Spain.
Please visit us on www.cerbomed.com .
About MARVAMED
MARVAMED, based in Genoa, is a distributor specializing in medical products for neuromodulation and functional neurosurgery. The company was founded in March 2010 by Dr. Pierluigi Bertolotto, who has 20 years of experience in the neurology market, in the area of movement disturbances and pain.
Contact:
Dr. Martin Hyca, Director Marketing & Sales
cerbomed GmbH
Phone:
0049 9131 9202 76 30
martin.hyca@cerbomed.com
or
Dr.
Pierluigi Bertolotto, CEO
MARVAMED
Phone: 0039 335481087
bertolotto@marvamed.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Kinaxis and Ottawa Senators Renew Partnership, Uniting National Capital Region26.6.2025 20:32:00 CEST | Press release
Bold partnership focuses on elevating community impact and brand presence Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is proud to announce a renewed three-year partnership with the Ottawa Senators and their AHL affiliate, the Belleville Senators. This collaboration is designed to amplify Kinaxis’ brand visibility, deepen community roots, and create unforgettable experiences for customers, prospects, and employees. As two proud Ottawa-based organizations, Kinaxis and the Senators will come together again to celebrate local talent, foster youth development, and drive meaningful community engagement. The partnership will also spotlight the Kinaxis brand across high-visibility platforms—including center ice at Canadian Tire Centre, LED rings, and digital dashboards during home and away games—ensuring a powerful presence throughout the NHL season. “At Kinaxis, we believe in the power of community and the importance of showing up where it matters most,” said
CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More26.6.2025 18:49:00 CEST | Press release
Purpose-built agents work around the clock to deliver external intelligence that transforms how enterprises make strategic decisions CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence. While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech
Pure Lithium and CEO Emilie Bodoin Recognized for Innovations at Reuters Global Energy Transition Awards26.6.2025 18:27:00 CEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has won the 2025 Reuters Global Energy Transition award for R&D Achievement. The award, presented at a June 24th ceremony in New York, recognizes research and development projects that promote a science-oriented energy transition while yielding promising potential and achievement. Pure Lithium has developed lithium metal batteries with double the energy density of lithium-ion cells and an industry-leading cycle life. By prioritizing research and development, the company achieved step-change advancements in battery technology and has built a strong portfolio of 119 patents and applications. “We’re thrilled to be selected for this prestigious award, which recognizes the hard work, dedication and creativity of our world-class team,” said Pure Lithium Founder and CEO Emilie Bodoin. “We know that commercializing a new chemistry requires a delicate balance of
Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector26.6.2025 16:41:00 CEST | Press release
Digital leader aims to capture rising cross-generational demand for public and private healthcare services amid demographic shift and urbanization trends.The launch of AQ enhances Ant Group’s comprehensive suite of AI solutions for healthcare, enabling medical institutions and doctors to offer more efficient, accessible, and personalized services. Ant Group today launched its AI healthcare app, AQ, to accelerate the company’s entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626728870/en/ Ant Group launched the AI healthcare app AQ to accelerate its entry into the healthcare sector By around 2035, over
Wasabi Technologies Becomes Official Cloud Storage Partner and Front-of-Jersey Sponsor of USA Rugby26.6.2025 16:00:00 CEST | Press release
USA Rugby partnership marks the latest addition to Wasabi’s robust sports sponsorship portfolio Wasabi Technologies, the hot cloud storage company, today announced it has strengthened its sports sponsorship program as the Official Cloud Storage Partner of USA Rugby. This milestone partnership unites two organizations committed to rapid growth, excellence, and technology innovation. Wasabi is purpose-built for media-rich industries like sports and entertainment and offers simple, fast, and predictable cloud storage for organizations with growing content archives. USA Rugby now stands alongside Wasabi’s compelling sponsorship portfolio of teams unlocking the power of their data, including iconic organizations, like the Boston Red Sox and Liverpool Football Club. “With digital transformation being top of mind for all sports organizations, we can’t think of a better partner than Wasabi to innovate alongside,” said USA Rugby CEO, Bill Goren. “Wasabi has established itself as a true industry
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum